⌘K
Loading ticker…
As of 2026-08-24, BioMarin Pharmaceuticals Inc (BMRN) has a 3-month relative strength percentile of 81 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 54. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 3.1%, relative volume 0.98×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
BMRN is in a stage 2 uptrend, week 4. Currently in a 8-day base; basing ADR 2.7% (broad 2.9%). VCP detected: no. RS line below base-start high. Distance from 50d / 200d: 7.0% / 13.6%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Positive EPS uses YoY change.
BMRN is held by 45 ETFs as of May 2026. Top owner: VHT at 0.17% weight, $31M notional. Top 3 carry $79M.
Held by 155 ETFs · $2.1B across latest filings · largest weight 4.09% (GNOM).
Top 10 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| VHTVanguard Health Care ETF | 0.17% | $31M | — |
| SCHMSchwab U.S. Mid-Cap ETF | 0.20% | $30M | −0.03 pp |
| IVOO | 0.31% | $18M | −0.03 pp |
| FNDA | 0.16% | $14M | — |
| SCHXSchwab U.S. Large-Cap ETF | 0.02% | $12M |
Strong relative strength, but attention is quiet relative to this name’s own recent norm. Academic work links low public attention to better forward returns on average — context to weigh, not a forecast.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| — |
| VONVVanguard Russell 1000 Value ETF | 0.03% | $7M | — |
| SCHBSchwab U.S. Broad Market ETF | 0.02% | $7M | — |
| IVOG | 0.34% | $6M | −0.03 pp |
| SCHVSchwab U.S. Large-Cap Value ETF | 0.04% | $6M | — |
| IVOV | 0.28% | $4M | −0.03 pp |
Showing 10 of 45 ETF owners.
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Related searches
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | BMRN Jan avg: -1.42% median: -4.23% win: 25% σ: 8.85% n: 4 2022-04-12 → 2026-07-31 | BMRN Feb avg: 1.45% median: 3.57% win: 50% σ: 11.81% n: 4 2022-04-12 → 2026-07-31 | BMRN Mar avg: -2.57% median: -1.51% win: 25% σ: 4.21% n: 4 2022-04-12 → 2026-07-31 | BMRN Apr avg: -5.11% median: -4.57% win: 0% σ: 3.61% n: 5 2022-04-12 → 2026-07-31 | BMRN May avg: -5.34% median: -7.65% win: 20% σ: 6.56% n: 5 2022-04-12 → 2026-07-31 | BMRN Jun avg: 2.84% median: -0.12% win: 40% σ: 6.85% n: 5 2022-04-12 → 2026-07-31 | BMRN Jul avg: 3.57% median: 3.84% win: 100% σ: 1.62% n: 5 2022-04-12 → 2026-07-31 | BMRN Aug avg: 4.12% median: 3.79% win: 100% σ: 3.06% n: 4 2022-04-12 → 2026-07-31 (current) | BMRN Sep avg: -9.53% median: -6.01% win: 0% σ: 9.07% n: 4 2022-04-12 → 2026-07-31 | BMRN Oct avg: -3.28% median: -3.67% win: 25% σ: 4.67% n: 4 2022-04-12 → 2026-07-31 | BMRN Nov avg: 8.25% median: 8.11% win: 100% σ: 7.33% n: 4 2022-04-12 → 2026-07-31 | BMRN Dec avg: 3.54% median: 4.17% win: 75% σ: 3.15% n: 4 2022-04-12 → 2026-07-31 |